Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 4/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 11/20 | 0.49 |
| ▸ | RXRB | P28702 | 11/20 | 0.49 |
| ▸ | RXRG | P48443 | 11/20 | 0.49 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19763054 | 0.81 | WNT3A (0.50) | WNT3ARXRARXRBRXRGGAA | |
| SCHEMBL12302553 | 0.77 | WNT3A (0.65) | WNT3AABCC4LMNAGAATSHR | |
| SCHEMBL30559520 | 0.76 | PLAU (0.43) | WNT3A | |
| SCHEMBL5149062 | 0.73 | ABCC4 (0.67) | WNT3ARXRARXRBRXRGABCC4 | |
| SCHEMBL18427891 | 0.73 | LMNA (0.86) | RXRARXRBRXRGABCC4LMNA | |
| SCHEMBL68027 | 0.73 | LMNA (0.86) | RXRARXRBRXRGABCC4LMNA | |
| SCHEMBL28936285 | 0.72 | KIF11 (0.48) | WNT3A | |
| SCHEMBL12126599 | 0.71 | LMNA (0.75) | PTGS2RXRARXRBRXRGABCC4 | |
| SCHEMBL30428004 | 0.71 | FFAR1 (0.46) | SYKGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL18427881 | 0.70 | ABCC4 (0.80) | PTGS2RXRARXRBRXRGABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251893-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators | NOVARTIS AG (CH) | 2019-04-09 | — | — | US | disclosed |
| US-20180000832-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2018-01-04 | — | — | US | disclosed |
| US-20160082014-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2016-03-24 | — | — | US | disclosed |
| US-20160082014-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2016-03-24 | — | — | US | disclosed |
| US-9238646-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as WNT signaling modulators | NOVARTIS AG (CH) | 2016-01-19 | — | — | US | disclosed |
| US-9238646-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as WNT signaling modulators | NOVARTIS AG (CH) | 2016-01-19 | — | — | US | disclosed |
| CN-102731379-B | N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as WNT signaling modulators | IRM LLC | 2015-05-06 | — | — | CN | disclosed |
| CN-102369187-B | N- (hetero) aryl, 2- (hetero) aryl substituted acetamides as WNT signal modulators | IRM LLC | 2014-06-04 | — | — | CN | disclosed |
| US-20130310375-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2013-11-21 | — | — | US | disclosed |
| US-8546396-B2 | N-(hetero)aryl, 2-(hetero)aryl—substituted acetamides for use as Wnt signaling modulators | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| CN-102731379-A | N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as wnt signaling modulators | IRM LLC | 2012-10-17 | — | — | CN | disclosed |
| CN-102369187-A | N- (hetero) aryl, 2- (hetero) aryl substituted acetamides as WNT signal modulators | IRM LLC | 2012-03-07 | — | — | CN | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| WO-2010101849-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310375-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, WNT3A, WNT3 | WNT3A 2/4885PTGS2 1130/4885RXRA 941/4885 |
| US-20160082014-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, CTNNA1 | WNT3A 4/4885PTGS2 1282/4885RXRA 670/4885 |
| US-10251893-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators | WNT1, CTNNB1, CTNNA1 | WNT3A 4/4885PTGS2 1282/4885RXRA 670/4885 |
| US-20180000832-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, CTNNA1 | WNT3A 4/4885PTGS2 1282/4885RXRA 670/4885 |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, WNT3A | WNT3A 3/4885PTGS2 807/4885RXRA 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.